Loading compound...

BTK inhibitor

Fenebrutinib is a small molecule drug that works as a tyrosine-protein kinase BTK inhibitor. It is currently being studied in clinical trials for various conditions, including multiple sclerosis, rheumatoid arthritis, and systemic lupus erythematosus.

How it worksFenebrutinib works by inhibiting a specific enzyme called tyrosine-protein kinase BTK.

Used for
Multiple sclerosisChronic progressive multiple sclerosisRheumatoid arthritisUrticariaSystemic lupus erythematosusType II hypersensitivity reaction disease
Conditions
Multiple sclerosisChronic progressive multiple sclerosisRheumatoid arthritisUrticariaSystemic lupus erythematosusType II hypersensitivity reaction disease
Class
BTK inhibitorSmall moleculeImmune system

How to take

This drug is currently in research phases (Max Phase 3) and is not yet widely approved for general use according to the provided data.

Talk to your doctor

Questions to ask

  • ·Is Fenebrutinib appropriate for my type of multiple sclerosis?
  • ·What are the risks of BTK inhibitors for my condition?
  • ·How will Fenebrutinib interact with my current lupus medications?

Educational summary derived from FDA labeling, AI-assisted. Not medical advice — consult a healthcare professional. Updated 2026-04-26.